CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. Read more about CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection.
The insulin-like growth factor axis and risk of liver disease in hepatitis C virus/HIV-co-infected women. Read more about The insulin-like growth factor axis and risk of liver disease in hepatitis C virus/HIV-co-infected women.
Association of cutaneous anergy with human papillomavirus and cervical neoplasia in HIV-seropositive and seronegative women. Read more about Association of cutaneous anergy with human papillomavirus and cervical neoplasia in HIV-seropositive and seronegative women.
Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. Read more about Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough.
Risk of cancers during interrupted antiretroviral therapy in the SMART study. Read more about Risk of cancers during interrupted antiretroviral therapy in the SMART study.
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. Read more about Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.
Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts. Read more about Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts.
Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. Read more about Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses.
Similar changes in plasmacytoid dendritic cell and CD4 T-cell counts during primary HIV-1 infection and treatment. Read more about Similar changes in plasmacytoid dendritic cell and CD4 T-cell counts during primary HIV-1 infection and treatment.
A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. Read more about A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals.
